公开(公告)号：US11008300B2

公开(公告)日：2021-05-18

申请号：US16744303

申请日：2020-01-16

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Yan Shi ,  Peter Tai Wah Cheng ,  Ying Wang ,  Jun Shi ,  Shiwei Tao ,  Jun Li ,  Lawrence J. Kennedy ,  Robert F. Kaltenbach, III ,  Hao Zhang ,  James R. Corte

IPC: C07D401/04 ,  C07D403/04 ,  C07D249/06 ,  A61P35/00 ,  A61P1/16 ,  A61P19/10 ,  A61P13/12 ,  A61P11/00 ,  C07C249/06 ,  C07C403/04

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US11007180B2

公开(公告)日：2021-05-18

申请号：US16732387

申请日：2020-01-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  Robert F. Kaltenbach, III ,  Jun Li ,  Jun Shi ,  Yan Shi ,  Shiwei Tao ,  Hao Zhang ,  Suresh Dhanusu ,  Kumaravel Selvakumar ,  Ramesh Babu Reddigunta ,  Steven J. Walker ,  Lawrence J. Kennedy ,  James R. Corte ,  Tianan Fang ,  Sutjano Jusuf

IPC: C07D401/04 ,  A61K31/4192 ,  C07D401/14 ,  C07D249/06 ,  A61K31/27 ,  A61K31/454 ,  A61K31/41 ,  C07C62/10

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.

公开(公告)号：US10071078B2

公开(公告)日：2018-09-11

申请号：US15628104

申请日：2017-06-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  Robert F. Kaltenbach, III ,  Jun Li ,  Jun Shi ,  Yan Shi ,  Shiwei Tao ,  Hao Zhang ,  Suresh Dhanusu ,  Kumaravel Selvakumar ,  Ramesh Babu Reddigunta ,  Steven J. Walker ,  Lawrence J. Kennedy ,  James R. Corte ,  Tianan Fang ,  Sutjano Jusuf

IPC: C07D401/04 ,  A61K31/4192 ,  A61K31/27 ,  A61K31/454 ,  C07D401/14 ,  C07D249/06 ,  A61K31/41 ,  C07C62/10

CPC classification number: A61K31/4192 ,  A61K31/27 ,  A61K31/41 ,  A61K31/454 ,  C07C62/10 ,  C07D249/06 ,  C07D401/04 ,  C07D401/14

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.